Cidara Therapeutics Inc. (CDTX)
20.86
-0.33 (-1.56%)
At close: Jan 14, 2025, 3:59 PM
17.00
-18.50%
Pre-market Jan 15, 2025, 04:23 AM EST
undefined% (undefined)
| Bid | 17 |
| Market Cap | 228.32M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -23.9 |
| PE Ratio (ttm) | -0.87 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 28.18 |
| Volume | 69,086 |
| Avg. Volume (20D) | 70,657 |
| Open | 21.02 |
| Previous Close | 21.19 |
| Day's Range | 20.82 - 22.27 |
| 52-Week Range | 10.00 - 28.42 |
| Beta | undefined |
About CDTX
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 15, 2015
Employees 69
Stock Exchange NASDAQ
Ticker Symbol CDTX
Website https://www.cidara.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 58.20% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Cidara Therapeutics Inc. is scheduled to release its earnings on Apr 21, 2025,
after market closes.
Analysts project revenue of $300.00K, reflecting a -98.29% YoY shrinking and earnings per share of -4.1, making a 412.50% increase YoY.
Analysts project revenue of $300.00K, reflecting a -98.29% YoY shrinking and earnings per share of -4.1, making a 412.50% increase YoY.
1 month ago ·
Source
+15.41%
Cidara Therapeutics shares are trading higher. The...
Unlock content with
Pro Subscription
8 months ago ·
Source
+5.78%
Cidara Therapeutics shares are trading higher after the company announced the divestiture of rezafungin to Mundipharma, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing.
